Insights into the Behavior of Triple-Negative MDA-MB-231 Breast Carcinoma Cells Following the Treatment with 17β-Ethinylestradiol and Levonorgestrel
Open Access
- 8 May 2021
- Vol. 26 (9), 2776
- https://doi.org/10.3390/molecules26092776
Abstract
Oral contraceptives (OCs) are widely used due to their efficiency in preventing unplanned pregnancies and treating several human illnesses. Despite their medical value, the toxicity of OCs remains a public concern. Previous studies indicate the carcinogenic potential of synthetic sex hormones and their link to the development and progression of hormone-dependent malignancies such as breast cancer. However, little is known about their influence on the evolution of triple-negative breast carcinoma (TNBC), a malignancy defined by the absence of estrogen, progesterone, and HER2 receptors. This study reveals that the active ingredients of modern OCs, 17β-Ethinylestradiol, Levonorgestrel, and their combination induce differential effects in MDA-MB-231 TNBC cells. The most relevant behavioral changes occurred after the 24 h treatment with 17β-Ethinylestradiol, summarized as follows: (i) decreased cell viability (64.32% at 10 µM); (ii) cell roundness and loss of confluence; (iii) apoptotic aspect of cell nuclei (fragmentation, membrane blebbing); and (iv) inhibited cell migration, suggesting a potential anticancer effect. Conversely, Levonorgestrel was generally associated with a proliferative activity. The association of the two OCs exerted similar effects as 17β-Ethinylestradiol but was less effective. Further studies are necessary to elucidate the hormones’ cytotoxic mechanism of action on TNBC cells.Funding Information
- The Romanian National Authority for Scientific Research and Innovation, CNCS –UEFISCDI (PN-III-P1-1.1-TE-2019-2134)
This publication has 65 references indexed in Scilit:
- Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessmentContraception, 2013
- Progesterone – promoter or inhibitor of breast cancerClimacteric, 2013
- Animal Models for Studying Prevention and Treatment of Breast CancerPublished by Elsevier BV ,2013
- Proliferative Effects of Estradiol- or Ethinylestradiol-Progestogen Combinations on Human Breast Cancer Cells in an Intermitted and a Long-term RegimenHormone and Metabolic Research, 2012
- Choosing the right cell line for breast cancer researchBreast Cancer Research, 2011
- History of oral contraceptionThe European Journal of Contraception & Reproductive Health Care, 2010
- Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanismsInternational Journal of Cancer, 2010
- Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptivesPatient Preference and Adherence, 2009
- Intrinsic Mechanism of Estradiol-Induced Apoptosis in Breast Cancer Cells Resistant to Estrogen DeprivationJNCI Journal of the National Cancer Institute, 2005
- Mechanism of action of levonorgestrel: In vitro metabolism and specific interactions with steroid receptors in target organsThe Journal of Steroid Biochemistry and Molecular Biology, 1992